jamesmaggs6 Sep 2009 17:01
This might be of interest, I copied it from an earlier post (5th August) but you may have missed it. Interesting.
''Another worth watching is Ark Therapeutics, focused on gene-based medicine but with a small revenue-producing wound care division, which has two products in Phase III stages. While kidney failure drug Trinam is just beginning US trials, Cerepro, a treatment for a fatal form of brain tumour, is expected to receive a decision from the European regulators in the second half of this year and, according to independent broker Nomura, this is ‘likely to be the major inflection point for the share price’. The stock, which topped 150p two years ago, has oscillated around 50p in the past year and could reward a speculation."